2023年3月3日

钱AI-powered药物发现最新消息©杰拉尔德/ pixabay.com mm Antiverse Ltd .)人工智能识别八抗体治疗人类潜力和提高€2.8年的资金内部持续发展。Antiverse有限公司报告了功能性抗体的发现集群目标两个G-protein-coupled受体(GPCRs),两者都是显示的绑定配置文件和摩尔的亲和力。与此同时,该公司宣布融资轮€2.8 (£2.5 m)从新的投资者InnoSpark AngelHub,明天Kadmos资本和规模,以及现有投资者,张量,深科学企业,埃德•帕金森和威尔士发展银行(瓦分贝)。GPCRs是最大、最多元化的集团在真核生物膜受体。他们调解我们的激素,我们的视觉,嗅觉味觉和疼痛和神经递质参与许多细胞识别过程。换句话说,GPCR信号是大部分生理过程的基础上,进而使他们特别有趣的制药工业。威尔士启动Antiverse有限公司成立于2017年计划投资从深科学企业,发展一种计算抗体药物发现平台针对这样的GPC受体。Antiverse平台驻留在结构生物学的交汇处,机器学习,医学加速和减少为代价的发现。平台是造型antibody-antigen交互使用机器学习和噬菌体展示方法。形成鲜明对比,这是传统的、复杂的、昂贵的和时间密集的流程GDCRs抗体的识别研究。 “Antiverse’s AI-powered methods to generate nanomolar binders against “difficult” antigens such as GPCRs in silico is a gamechanger in the antibody discovery industry, the most important innovation since the invention of phage display. We will see large savings in cost and time in the discovery and development of antibodies”, explained Peter Pack, antibody engineer and NED at Antiverse. With only few FDA-approved antibody therapeutics in the game against over 30 illnesses that have been associated with GPCRs, the stakes are high, but the company hopes to commercialize their product after further development. Share